Cargando…
Tissue-engineered 3D melanoma model with blood and lymphatic capillaries for drug development
While being the rarest skin cancer, melanoma is also the deadliest. To further drug discovery and improve clinical translation, new human cell-based in vitro models are needed. Our work strives to mimic the melanoma microenvironment in vitro as an alternative to animal testing. We used the self-asse...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123405/ https://www.ncbi.nlm.nih.gov/pubmed/30181613 http://dx.doi.org/10.1038/s41598-018-31502-6 |
_version_ | 1783352832921960448 |
---|---|
author | Bourland, Jennifer Fradette, Julie Auger, François A. |
author_facet | Bourland, Jennifer Fradette, Julie Auger, François A. |
author_sort | Bourland, Jennifer |
collection | PubMed |
description | While being the rarest skin cancer, melanoma is also the deadliest. To further drug discovery and improve clinical translation, new human cell-based in vitro models are needed. Our work strives to mimic the melanoma microenvironment in vitro as an alternative to animal testing. We used the self-assembly method to produce a 3D human melanoma model exempt of exogenous biomaterial. This model is based on primary human skin cells and melanoma cell lines while including a key feature for tumor progression: blood and lymphatic capillaries. Major components of the tumor microenvironment such as capillaries, human extracellular matrix, a stratified epidermis (involucrin, filaggrin) and basement membrane (laminin 332) are recapitulated in vitro. We demonstrate the persistence of CD31(+) blood and podoplanin(+)/LYVE-1(+) lymphatic capillaries in the engineered tissue. Chronic treatment with vemurafenib was applied to the model and elicited a dose-dependent response on proliferation and apoptosis, making it a promising tool to test new compounds in a human-like environment. |
format | Online Article Text |
id | pubmed-6123405 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-61234052018-09-10 Tissue-engineered 3D melanoma model with blood and lymphatic capillaries for drug development Bourland, Jennifer Fradette, Julie Auger, François A. Sci Rep Article While being the rarest skin cancer, melanoma is also the deadliest. To further drug discovery and improve clinical translation, new human cell-based in vitro models are needed. Our work strives to mimic the melanoma microenvironment in vitro as an alternative to animal testing. We used the self-assembly method to produce a 3D human melanoma model exempt of exogenous biomaterial. This model is based on primary human skin cells and melanoma cell lines while including a key feature for tumor progression: blood and lymphatic capillaries. Major components of the tumor microenvironment such as capillaries, human extracellular matrix, a stratified epidermis (involucrin, filaggrin) and basement membrane (laminin 332) are recapitulated in vitro. We demonstrate the persistence of CD31(+) blood and podoplanin(+)/LYVE-1(+) lymphatic capillaries in the engineered tissue. Chronic treatment with vemurafenib was applied to the model and elicited a dose-dependent response on proliferation and apoptosis, making it a promising tool to test new compounds in a human-like environment. Nature Publishing Group UK 2018-09-04 /pmc/articles/PMC6123405/ /pubmed/30181613 http://dx.doi.org/10.1038/s41598-018-31502-6 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Bourland, Jennifer Fradette, Julie Auger, François A. Tissue-engineered 3D melanoma model with blood and lymphatic capillaries for drug development |
title | Tissue-engineered 3D melanoma model with blood and lymphatic capillaries for drug development |
title_full | Tissue-engineered 3D melanoma model with blood and lymphatic capillaries for drug development |
title_fullStr | Tissue-engineered 3D melanoma model with blood and lymphatic capillaries for drug development |
title_full_unstemmed | Tissue-engineered 3D melanoma model with blood and lymphatic capillaries for drug development |
title_short | Tissue-engineered 3D melanoma model with blood and lymphatic capillaries for drug development |
title_sort | tissue-engineered 3d melanoma model with blood and lymphatic capillaries for drug development |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123405/ https://www.ncbi.nlm.nih.gov/pubmed/30181613 http://dx.doi.org/10.1038/s41598-018-31502-6 |
work_keys_str_mv | AT bourlandjennifer tissueengineered3dmelanomamodelwithbloodandlymphaticcapillariesfordrugdevelopment AT fradettejulie tissueengineered3dmelanomamodelwithbloodandlymphaticcapillariesfordrugdevelopment AT augerfrancoisa tissueengineered3dmelanomamodelwithbloodandlymphaticcapillariesfordrugdevelopment |